Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Yale Research Projects Exploring New Uses for Failed Drugs get NIH Funding

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Two Yale School of Medicine research programs are among nine nationally to receive grants under a new federal program.

Federal Program is designed to take drugs that have had disappointing therapeutic results in one disease and investigate their use in different diseases.

National Center for Advancing Translational Sciences (NCAT) of the National Institutes of Health announced June 18 that it will fund Alzheimer’s research headed by neurobiologist Stephen Strittmatter and schizophrenia research led by John Krystal, chair of psychiatry at the Yale School of Medicine.

The NCAT grants totaled $12.7 million.

The average length of time from target discovery to approval of a new drug is about 13 years, and the failure rate exceeds 95 percent, the agency estimates. During that period, pharmaceutical companies have already made substantial investments in testing on potential drugs, for instance establishing their safety. The program aims to recoup that investment by investigating whether drugs might work on different diseases.

Strittmatter, the Vincent Coates Professor of Neurology, will investigate whether an AstraZeneca cancer drug might help treat patients with Alzheimer’s. The AstraZeneca cancer drug acts on the same molecular pathway that Strittmatter’s lab has identified as a potential cause of damage to neurons found in Alzheimer’s disease. When disrupted, the pathway can harm learning and memory in mice.

“This gives us a chance to shave years off the development process,” Strittmatter said. “If even one of these 12 projects succeeds, the program will be a home run.”

Dr. Haakon Berge Nygaard and Dr. Christopher H. Van Dyck are co-investigators on the project.
Krystal will investigate whether a drug that Pfizer has ceased developing might help rehabilitate schizophrenics. The drug acts upon brain systems governed by neurotransmitter glutamate, which Krystal’s lab has shown is a promising therapeutic target.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!